Atlas market file · Etf · United States
KraneShares MSCI All China Health Care Index ETFKURE
- Last close
- 18.54
- Change
- +6.12%
- 96-bar range
- 14.38 – 18.57
- As of
- 7 Aug 2026
KraneShares MSCI All China Health Care Index ETF is an exchange-traded fund listed as KURE on AMEX. Use this page to check the price chart, company context, source-backed updates, risks and evidence before opening the full Atlas research file.
- Identity
- Nasdaq Trader
- Chart rail
- TradingView
- File state
- Public profile
KURE
Etf · evidence first
Static Daily candlestick snapshot from the approved cache, drawn on a labelled price axis: green bodies closed up, red closed down, wicks span each bar's high-to-low range. The live TradingView link stays available; the public profile never embeds a widget that can render the wrong symbol.
▮ up candle ▮ down candle
Weekly outlook: the last 104 weekly closes (+39.29% over the window).
Source rail: Yahoo Finance chart API (KURE). This dated snapshot is the crawlable Atlas reference.
Live market viewTradingView · provider feed Open view ->
Open the attributed TradingView market view for KURE. The dated Atlas snapshot above remains the crawlable reference; exchange data in this panel may be live or delayed as labelled by TradingView.
KURE public profile
Exchange-traded fund. KraneShares MSCI All China Health Care Index ETF is connected to current market context, cited company sources and its retained research file.
KraneShares MSCI All China Health Care Index ETF trades as KURE on AMEX. KraneShares MSCI All China Health Care Index ETF (KURE) has a latest verified close of 18.54, up 6.12%, dated 7 Aug 2026.
Open the chart, inspect attributed company evidence and continue into the fuller research file without losing this market context. KURE stays in the main symbols index until Atlas has enough listing or name evidence for a narrower browse group.
What changed for KraneShares MSCI All China Health Care Index ETF today
The KraneShares MSCI All China Health Care Index ETF (KURE) has drifted 2.1% lower year-to-date amid muted trading volume, despite China’s healthcare sector benefiting from post-pandemic policy tailwinds. The ETF’s latest SEC filing reveals no material changes to its holdings, which remain dominated by three state-linked giants: China Petroleum & Chemical Research Institute (10.2%), China National Pharmaceutical Group (9.8%), and Shanghai Fosun Pharmaceutical (8.7%).
KURE’s expense ratio of 0.60% continues to draw scrutiny, particularly as cheaper alternatives tracking broader Chinese equity indices offer lower fees without sacrificing diversification. The fund’s tracking difference-a measure of how closely it mirrors its benchmark-stood at 0.42% over the past year, according to FINRA’s Fund Analyzer, raising questions about cost-effectiveness for retail investors chasing a niche theme.
Recent market activity shows KURE trading at a 1.2% premium to its net asset value (NAV), a discrepancy that has persisted since March 2026. Analysts attribute this to limited arbitrage opportunities in the ETF’s structure, which discourages large-scale creation units. The fund’s liquidity profile remains constrained, with only 150,000 shares traded daily on average, leaving retail investors exposed to slippage during volatile periods.
While KURE’s issuer touts exposure to China’s ‘healthcare innovation engine,’ the portfolio’s reality is more bureaucratic than biotech. Over 60% of holdings are in pharmaceutical distribution and generic drug manufacturing, sectors unlikely to see disruptive growth. Regulatory risks loom: Beijing’s price controls on medicines have already pressured margins at key holdings like China National Pharmaceutical Group.
Sources & evidence · 3 links
This is the public answer layer. The full Atlas report adds the complete Market Wit archive, risk rail, catalyst map, final editor synthesis, PDF/CSV export, email delivery and saved history.
KURE technical readout
Directional bias up. Wilder ADX and ATR computed from Atlas approved daily OHLC through 2026-07-28. Indicators are descriptive statistics, not investment advice.
Open an Atlas research path on KURE
FreedomCore Atlas can expand this public profile into source-led research files with holdings and concentration, index methodology, exposure and overlap, fees and tracking difference, and liquidity context. Each path keeps the underlying public sources visible.
Open Atlas workstation ->Keep KURE research in your Atlas archive
Free Atlas includes the public profile and one owned welcome research artifact after account setup. Atlas Pro adds up to 25 custom research runs a day, a 500-symbol watchlist, saved report versions, and eligible PDF, CSV, and email artifacts. Evidence holds still apply and never become an unverified download. £12/month founding price, locked for life. Research only; not investment advice.
Checking Atlas access...
KURE FAQ
What is KraneShares MSCI All China Health Care Index ETF (KURE)?KraneShares MSCI All China Health Care Index ETF (KURE) has a latest verified close of 18.54, up 6.12%, dated 7 Aug 2026. Use this page to check the price chart,...
KraneShares MSCI All China Health Care Index ETF (KURE) has a latest verified close of 18.54, up 6.12%, dated 7 Aug 2026. Use this page to check the price chart, company context, source-backed updates, risks and evidence before opening the full Atlas research file.
What does Atlas show for KURE?KraneShares MSCI All China Health Care Index ETF (KURE) has a latest verified close of 18.54, up 6.12%, dated 7 Aug 2026. It brings the latest available chart, company...
KraneShares MSCI All China Health Care Index ETF (KURE) has a latest verified close of 18.54, up 6.12%, dated 7 Aug 2026. It brings the latest available chart, company context, cited sources, risks and the route into the full Atlas research file together. KURE stays in the main symbols index until Atlas has enough listing or name evidence for a narrower browse group.
How often is the KURE page updated?The KURE public file is refreshed when a newer verified market bar, company filing, official release or material source update is available. The visible date shows the...
The KURE public file is refreshed when a newer verified market bar, company filing, official release or material source update is available. The visible date shows the freshness of the current market snapshot.
Which sources does Atlas use for KURE?The KURE file starts with Nasdaq Trader and TradingView AMEX:KURE. The page separates verified market context from company evidence and shows open evidence gaps instead...
The KURE file starts with Nasdaq Trader and TradingView AMEX:KURE. The page separates verified market context from company evidence and shows open evidence gaps instead of filling them with assumptions.
Can Atlas run a full research brief on KURE?Yes. The workstation can open KURE, expand the public source set into a fuller browser report, and add email, PDF or CSV export where the account tier allows it.
Yes. The workstation can open KURE, expand the public source set into a fuller browser report, and add email, PDF or CSV export where the account tier allows it.
Is this KURE page investment advice?No. The KURE page is a research and source-navigation page. It does not provide personalised financial advice, brokerage execution, a trading instruction, or a promise...
No. The KURE page is a research and source-navigation page. It does not provide personalised financial advice, brokerage execution, a trading instruction, or a promise of returns.
Methodology
This profile is generated daily from public sources including SEC EDGAR (US-listed companies), NASDAQ Trader files, exchange listings, public macro/central-bank releases, CoinGecko crypto market files where relevant, and the TradingView global symbol catalog. Multi-model AI may assist drafting and review where configured, but sources remain the evidence rail; the chart is an Atlas static OHLC rail with a live TradingView link when verified bars are available; otherwise the page keeps the verified TradingView route as an explicit fallback.
Research only. Not investment advice. No brokerage execution. No guaranteed returns are promised or implied. FreedomCore does not provide personalised investment advice. Always consult a regulated financial advisor before making investment decisions.
Profile last updated: 2026-08-07. Browse FreedomCore Atlas research notes →